文献速递胃肠动力与功能性疾病

组胺1受体拮抗剂依巴斯汀治疗非便秘型肠易激综合征:一项随机双盲安慰剂对照试验

Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Gut · 2024-02-23

该随机双盲安慰剂对照2期研究纳入202例符合Rome III标准的非便秘型肠易激综合征患者,随机接受依巴斯汀20 mg或安慰剂治疗12周。依巴斯汀组达到GRS+API复合终点应答比例显著高于安慰剂组(12% vs 4%,p=0.047),而GRS和API单独应答率组间差异未达统计学显著。作者认为依巴斯汀优于安慰剂,应进一步评估其作为非便秘型肠易激综合征新治疗的价值。

要点

  • 依巴斯汀20 mg治疗12周使12%患者达到GRS+API复合终点应答,安慰剂组为4%,差异有统计学意义(p=0.047)。
  • GRS单独应答率依巴斯汀组15% vs 安慰剂组7%(p=0.072),API单独应答率37% vs 25%(p=0.081),均未达统计学显著。
  • 作者认为依巴斯汀优于安慰剂,应进一步评估作为非便秘型肠易激综合征的新治疗。

核心结论

  • 研究表明依巴斯汀优于安慰剂,应进一步评估作为非便秘型肠易激综合征患者的新治疗。

研究设计与样本

  • 随机、双盲、安慰剂对照2期研究,纳入符合Rome III标准的非便秘型肠易激综合征患者202例(32±11岁,68%女性),随机分配至依巴斯汀20 mg组(n=101)或安慰剂组(n=101),治疗12周。

主要发现

  • GRS+API复合终点应答率依巴斯汀组为12%(12/92),安慰剂组为4%(4/87),p=0.047。
  • GRS单独应答率依巴斯汀组为15%(14/91),安慰剂组为7%(6/87),p=0.072。
  • API单独应答率依巴斯汀组为37%(34/92),安慰剂组为25%(20/85),p=0.081。

关键数值与推荐

  • GRS周应答者定义为报告症状完全或明显缓解;API周应答者定义为每周平均疼痛评分较基线降低至少30%。
  • 主要终点为12个治疗周中至少6周同时达到GRS和API周应答(GRS+API复合终点)的比例,以及GRS和API单独应答的比例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated the histamine 1 receptor antagonist ebastine as a potential treatment for patients with non-constipated irritable bowel syndrome (IBS) in a randomised, placebo-controlled phase 2 study. METHODS: Non-constipated patients with IBS fulfilling the Rome III criteria were randomly assigned to 20 mg ebastine or placebo for 12 weeks. Subjects scored global relief of symptoms (GRS) and abdominal pain intensity (API). A subject was considered a weekly responder for GRS if total or obvious relief was reported and a responder for API if the weekly average pain score was reduced by at least 30% vs baseline. The primary endpoints were the proportion of subjects who were weekly responders for at least 6 out of the 12 treatment weeks for both GRS and API ('GRS+API', composite endpoint) and for GRS and API separately. RESULTS: 202 participants (32±11 years, 68% female) were randomly allocated to receive ebastine (n=101) or placebo (n=101). Treatment with ebastine resulted in significantly more responders (12%, 12/92) for GRS+API compared with placebo (4%, 4/87, p=0.047) while the proportion of responders for GRS and API separately was higher for ebastine compared with placebo, although not statistically significant (placebo vs ebastine, GRS: 7% (6/87) vs 15% (14/91), p=0.072; API: 25% (20/85) vs 37% (34/92), p=0.081). CONCLUSIONS: Our study shows that ebastine is superior to placebo and should be further evaluated as novel treatment for patients with non-constipated IBS. TRIAL REGISTRATION NUMBER: The study protocol was approved by the local ethics committee of each study site (EudraCT number: 2013-001199-39; ClinicalTrials.gov identifier: NCT01908465).

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Decraecker L, De Looze D, Hirsch DP, et al. Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial. Gut. 2024. PMID: 38191268. doi:10.1136/gutjnl-2023-331634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。